These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 33358557)

  • 1. Commercial immunoglobulin products contain cross-reactive but not neutralizing antibodies against SARS-CoV-2.
    Ahn TS; Han B; Krogstad P; Bun C; Kohn LA; Garcia-Lloret MI; Damoiseaux R; Butte MJ
    J Allergy Clin Immunol; 2021 Mar; 147(3):876-877. PubMed ID: 33358557
    [No Abstract]   [Full Text] [Related]  

  • 2. Characterization of SARS-CoV-2-specific antibodies in COVID-19 patients reveals highly potent neutralizing IgA.
    Zeng W; Ma H; Ding C; Yang Y; Sun Y; Huang X; He W; Xiang Y; Gao Y; Jin T
    Signal Transduct Target Ther; 2021 Jan; 6(1):35. PubMed ID: 33514692
    [No Abstract]   [Full Text] [Related]  

  • 3. Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351).
    Moyo-Gwete T; Madzivhandila M; Makhado Z; Ayres F; Mhlanga D; Oosthuysen B; Lambson BE; Kgagudi P; Tegally H; Iranzadeh A; Doolabh D; Tyers L; Chinhoyi LR; Mennen M; Skelem S; Marais G; Wibmer CK; Bhiman JN; Ueckermann V; Rossouw T; Boswell M; de Oliveira T; Williamson C; Burgers WA; Ntusi N; Morris L; Moore PL
    N Engl J Med; 2021 Jun; 384(22):2161-2163. PubMed ID: 33826816
    [No Abstract]   [Full Text] [Related]  

  • 4. Structure-based development of human antibody cocktails against SARS-CoV-2.
    Wang N; Sun Y; Feng R; Wang Y; Guo Y; Zhang L; Deng YQ; Wang L; Cui Z; Cao L; Zhang YJ; Li W; Zhu FC; Qin CF; Wang X
    Cell Res; 2021 Jan; 31(1):101-103. PubMed ID: 33262454
    [No Abstract]   [Full Text] [Related]  

  • 5. Neutralizing SARS-CoV-2.
    Poeschla E
    Elife; 2020 Dec; 9():. PubMed ID: 33320086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of vaccine-elicited antibody levels and neutralizing activities against SARS-CoV-2 and its variants.
    Liu J; Bodnar BH; Padhiar NH; Khan AI; Meng F; Saribas S; Wang P; Wang X; McCluskey E; Shah S; Zhao H; Luo JJ; Hu WH; Ho WZ
    Clin Transl Med; 2021 Dec; 11(12):e644. PubMed ID: 34923762
    [No Abstract]   [Full Text] [Related]  

  • 7. Distinct neutralization profile of spike variants by antibodies induced upon SARS-CoV-2 infection or vaccination.
    Rosati M; Terpos E; Agarwal M; Karalis V; Bear J; Burns R; Hu X; Papademetriou D; Ntanasis-Stathopoulos I; Trougakos IP; Dimopoulos MA; Pavlakis GN; Felber BK
    Am J Hematol; 2022 Jan; 97(1):E3-E7. PubMed ID: 34674297
    [No Abstract]   [Full Text] [Related]  

  • 8. Fc effector cross-reactivity: A hidden arsenal against SARS-CoV-2's evasive maneuvering.
    Grunst MW; Uchil PD
    Cell Rep Med; 2022 Feb; 3(2):100540. PubMed ID: 35233551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular deconvolution of the neutralizing antibodies induced by an inactivated SARS-CoV-2 virus vaccine.
    Zhou X; Wang H; Ji Q; Du M; Liang Y; Li H; Li F; Shang H; Zhu X; Wang W; Jiang L; Stepanov AV; Ma T; Gong N; Jia X; Gabibov AG; Lou Z; Lu Y; Guo Y; Zhang H; Yang X
    Protein Cell; 2021 Oct; 12(10):818-823. PubMed ID: 33909239
    [No Abstract]   [Full Text] [Related]  

  • 10. Spike Protein Antibodies Mediate the Apparent Correlation between SARS-CoV-2 Nucleocapsid Antibodies and Neutralization Test Results.
    Perkmann T; Koller T; Perkmann-Nagele N; Klausberger M; Duerkop M; Holzer B; Hartmann B; Mucher P; Radakovics A; Ozsvar-Kozma M; Wagner OF; Binder CJ; Haslacher H
    Microbiol Spectr; 2021 Sep; 9(1):e0021821. PubMed ID: 34132615
    [No Abstract]   [Full Text] [Related]  

  • 11. Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection.
    Rosati M; Terpos E; Ntanasis-Stathopoulos I; Agarwal M; Bear J; Burns R; Hu X; Korompoki E; Donohue D; Venzon DJ; Dimopoulos MA; Pavlakis GN; Felber BK
    Front Immunol; 2021; 12():793953. PubMed ID: 34899762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No crossreactivity of anti-SARS-CoV-2 spike protein antibodies with Syncytin-1.
    Prasad M; Lin JL; Gu Y; Gupta R; Macary P; Schwarz H
    Cell Mol Immunol; 2021 Nov; 18(11):2566-2568. PubMed ID: 34645941
    [No Abstract]   [Full Text] [Related]  

  • 13. A Possible Role for Anti-idiotype Antibodies in SARS-CoV-2 Infection and Vaccination.
    Murphy WJ; Longo DL
    N Engl J Med; 2022 Jan; 386(4):394-396. PubMed ID: 34818473
    [No Abstract]   [Full Text] [Related]  

  • 14. Avidity assay to test functionality of anti-SARS-Cov-2 antibodies.
    Gaspar EB; De Gaspari E
    Vaccine; 2021 Mar; 39(10):1473-1475. PubMed ID: 33581919
    [No Abstract]   [Full Text] [Related]  

  • 15. Emerging SARS-CoV-2 variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodies.
    Hu J; Peng P; Wang K; Fang L; Luo FY; Jin AS; Liu BZ; Tang N; Huang AL
    Cell Mol Immunol; 2021 Apr; 18(4):1061-1063. PubMed ID: 33633321
    [No Abstract]   [Full Text] [Related]  

  • 16. Characterization of a Broadly Neutralizing Monoclonal Antibody against SARS-CoV-2 Variants.
    Zakir TS; Meng T; Carmen LCP; Chu JJH; Lin RTP; Prabakaran M
    Viruses; 2022 Jan; 14(2):. PubMed ID: 35215823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralizing antibody response elicited by SARS-CoV-2 receptor-binding domain.
    Huang PH; Tsai HH; Liao BH; Lin YL; Jan JT; Tao MH; Chou YC; Hu CJ; Chen HW
    Hum Vaccin Immunother; 2021 Mar; 17(3):654-655. PubMed ID: 32991231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional Analysis of Human and Feline Coronavirus Cross-Reactive Antibodies Directed Against the SARS-CoV-2 Fusion Peptide.
    Vanderheijden N; Stevaert A; Xie J; Ren X; Barbezange C; Noppen S; Desombere I; Verhasselt B; Geldhof P; Vereecke N; Stroobants V; Oh D; Vanhee M; Naesens LMJ; Nauwynck HJ
    Front Immunol; 2021; 12():790415. PubMed ID: 35069571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-based development of three- and four-antibody cocktails against SARS-CoV-2 via multiple mechanisms.
    Sun Y; Wang L; Feng R; Wang N; Wang Y; Zhu D; Xing X; Yang P; Zhang Y; Li W; Wang X
    Cell Res; 2021 May; 31(5):597-600. PubMed ID: 33782529
    [No Abstract]   [Full Text] [Related]  

  • 20. Measuring cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine (BNT126b2) in patients on maintenance haemodialysis.
    Martin P; Clarke C
    EBioMedicine; 2021 Sep; 71():103567. PubMed ID: 34454401
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.